Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion reconfirmed that while it signed an MOU with Yesan County for a KRW 300.0B facility investment, the specific details of the investment plan remain unconfirmed.
📊 [Key Disclosure Details & Financial Highlights]
- Details of Rumor or Report
- Content: Report regarding Celltrion building a Chungnam plant with “KRW 300.0B investment by 2028”
- Media Outlet: Seoul Economic Daily and other media outlets
- Initial Report Date: December 01, 2023
- Clarification (Unconfirmed Status)
- Celltrion signed a Memorandum of Understanding (MOU) with Yesan County, Chungcheongnam-do, for a KRW 300.0B investment to build a biopharmaceutical and related materials plant by December 2028.
- Detailed investment plans are scheduled to be finalized in the future.
- This disclosure is a periodic re-disclosure following the initial report clarification on December 01, 2023.
- Re-disclosure Schedule
- Previous Related Disclosures: 2023-12-01, 2023-12-29, 2024-03-29
- Expected Next Re-disclosure Date: March 27, 2025 (or when specific details are confirmed)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Investment Plan Confirmation and Subsequent Re-disclosures
This filing serves as a routine re-disclosure stating that specific investment details remain unconfirmed following the signing of the MOU for the facility in Yesan. Tracking whether final plans—such as concrete capital expenditure amounts and construction timelines—are finalized is important for understanding the execution of the company’s domestic CAPEX plans. Detailed updates can be verified in future clarification disclosures (Confirmed/Unconfirmed) and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
